2015
DOI: 10.1074/jbc.m114.615716
|View full text |Cite
|
Sign up to set email alerts
|

Integrin α1-null Mice Exhibit Improved Fatty Liver When Fed a High Fat Diet Despite Severe Hepatic Insulin Resistance

Abstract: Background: Integrins regulate insulin signaling, but how they affect hepatic metabolism in vivo is unknown. Results: Integrin ␣1-null mice on a high fat diet display severe hepatic insulin resistance and decreased hepatic fat accumulation. Conclusion: Integrin ␣1␤1 protects against hepatic insulin resistance while promoting fatty liver upon nutrient overload. Significance: Integrin ␣1␤1 regulates hepatic insulin action and lipid accumulation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
28
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 42 publications
(35 citation statements)
references
References 57 publications
(50 reference statements)
2
28
1
Order By: Relevance
“…Pharmacological progress in blocking integrin α1 on human immune cells to reduce inflammation has, nevertheless, been slow, although anti-VLA-1 antibody treatment has been suggested to be beneficial to treat inflammatory conditions, such as rheumatoid arthritis and psoriasis, that involve localized pathological memory T-cells, (Gardner, 2014). A role for α1β1 in liver has recently been discovered, almost 20 years after the original integrin α1 −/− mouse strain was created, and recent data show that severity of obesity-induced fatty liver disease is attenuated in integrin α1 −/− mice (Williams et al, 2015). Although α1β1 is the only collagen receptor on hepatocytes (Gullberg et al, 1990), it does not seem to be involved in liver fibrosis.…”
Section: α10β1mentioning
confidence: 99%
“…Pharmacological progress in blocking integrin α1 on human immune cells to reduce inflammation has, nevertheless, been slow, although anti-VLA-1 antibody treatment has been suggested to be beneficial to treat inflammatory conditions, such as rheumatoid arthritis and psoriasis, that involve localized pathological memory T-cells, (Gardner, 2014). A role for α1β1 in liver has recently been discovered, almost 20 years after the original integrin α1 −/− mouse strain was created, and recent data show that severity of obesity-induced fatty liver disease is attenuated in integrin α1 −/− mice (Williams et al, 2015). Although α1β1 is the only collagen receptor on hepatocytes (Gullberg et al, 1990), it does not seem to be involved in liver fibrosis.…”
Section: α10β1mentioning
confidence: 99%
“…In one study, tail-vein injection of HFD-fed mice with a hydrolase for hyaluronan, an ECM component, reduces features of muscle and liver insulin resistance (Kang et al, 2013). Moreover, integrin-α1-subunit-deficient mice ( Itga1 −/− ) fed an HFD display reduced fatty liver content but also severe hepatic insulin resistance, compared to wild-type HFD-fed controls (Williams et al, 2015b). …”
Section: Discussionmentioning
confidence: 99%
“…Physiological, integrinmediated cell-ECM communication is critical not only normal ␤-cell function and indeed survival, as discussed here, but also for insulin action on its target tissues. Pathological modification of the ECM in type 2 diabetes, for example by high-fat diet, hyperglycemia-induced advanced glycation end-products (AGEs), or inflammatory cytokine-induced fibrosis, has thus been shown to participate in the insulin resistance state of insulin-targeted tissues (muscle, adipose tissue, and liver) and could impair ␤-cell function in a similar fashion (4,50,59,107,138,146,147). Deleterious cytokines that are elevated in the circulation of individuals with type 2 diabetes directly affect the expression of proteins of different functional classes including the actin cytoskeleton in ␤-cells (103); perhaps this may also occur in target cells to modulate their insulin sensitivity.…”
Section: Cytoskeleton and Fa Remodeling In Type 2 Diabetes: Parallelsmentioning
confidence: 98%